Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Gagnon

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Hepatology Communications|January 29, 2026
Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathyArun B Jesudian, Patrick Gagnon-Sanschagrin, Rebecca Bungay, et al.
Advances in Therapy|April 7, 2025
Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims DataArun Jesudian, Patrick Gagnon-Sanschagrin, Jessica Maitland, et al.
Current Medical Research and Opinion|August 24, 2021
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims studyJeff Schein, Ann Childress, Julie Adams, et al.
Journal of Medical Economics|July 5, 2024
The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database studyPatrick Gagnon-Sanschagrin, Myrlene Sanon, Mikhaïl Davidson, et al.
BMC Psychiatry|September 28, 2022
Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population - a machine learning approachPatrick Gagnon-Sanschagrin, Jeff Schein, Annette Urganus, et al.
Journal of Medical Economics|January 24, 2022
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspectiveJeff Schein, Lenard A Adler, Ann Childress, et al.
Rheumatology and Therapy|April 8, 2025
Burden of Glucocorticoid Use and Risk of Toxicities Among Patients with Immunoglobulin-G4-Related Disease: A Retrospective US-Based Claims StudyZachary S Wallace, Jenny Y Park, Elizabeth Serra, et al.
Journal of Medical Economics|January 7, 2018
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populationsEytan M Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, et al.
Journal of Managed Care & Specialty Pharmacy|November 22, 2021
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspectiveJeff Schein, Lenard A Adler, Ann Childress, et al.
Clinical and Translational Gastroenterology|January 21, 2025
Real-World Trends and Future Projections of the Prevalence of Cirrhosis and Hepatic Encephalopathy Among Commercially and Medicare-Insured Adults in the United StatesRobert J Wong, Patrick Gagnon-Sanschagrin, Zeev Heimanson, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Hepatology Communications|January 29, 2026
Rifaximin reduces rehospitalization risk in patients with cirrhosis and overt hepatic encephalopathyArun B Jesudian, Patrick Gagnon-Sanschagrin, Rebecca Bungay, et al.
Advances in Therapy|April 7, 2025
Assessment of Access Barriers to Rifaximin Among Patients with Hepatic Encephalopathy Using Adjudicated Claims DataArun Jesudian, Patrick Gagnon-Sanschagrin, Jessica Maitland, et al.
Current Medical Research and Opinion|August 24, 2021
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims studyJeff Schein, Ann Childress, Julie Adams, et al.
Journal of Medical Economics|July 5, 2024
The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database studyPatrick Gagnon-Sanschagrin, Myrlene Sanon, Mikhaïl Davidson, et al.
BMC Psychiatry|September 28, 2022
Identifying individuals with undiagnosed post-traumatic stress disorder in a large United States civilian population - a machine learning approachPatrick Gagnon-Sanschagrin, Jeff Schein, Annette Urganus, et al.
Journal of Medical Economics|January 24, 2022
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspectiveJeff Schein, Lenard A Adler, Ann Childress, et al.
Rheumatology and Therapy|April 8, 2025
Burden of Glucocorticoid Use and Risk of Toxicities Among Patients with Immunoglobulin-G4-Related Disease: A Retrospective US-Based Claims StudyZachary S Wallace, Jenny Y Park, Elizabeth Serra, et al.
Journal of Medical Economics|January 7, 2018
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populationsEytan M Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, et al.
Journal of Managed Care & Specialty Pharmacy|November 22, 2021
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspectiveJeff Schein, Lenard A Adler, Ann Childress, et al.
Clinical and Translational Gastroenterology|January 21, 2025
Real-World Trends and Future Projections of the Prevalence of Cirrhosis and Hepatic Encephalopathy Among Commercially and Medicare-Insured Adults in the United StatesRobert J Wong, Patrick Gagnon-Sanschagrin, Zeev Heimanson, et al.
Pageof 6